| Literature DB >> 19356717 |
Hiroyuki Mori1, Ken Inoki, Heike Münzberg, Darren Opland, Miro Faouzi, Eneida C Villanueva, Tsuneo Ikenoue, David Kwiatkowski, Ormond A MacDougald, Martin G Myers, Kun-Liang Guan.
Abstract
The mammalian target of rapamycin (mTOR) promotes anabolic cellular processes in response to growth factors and metabolic cues. The TSC1 and TSC2 tumor suppressors are major upstream inhibitory regulators of mTOR signaling. Mice with Rip2/Cre-mediated deletion of Tsc1 (Rip-Tsc1cKO mice) developed hyperphagia and obesity, suggesting that hypothalamic disruption (for which Rip2/Cre is well known) of Tsc1 may dysregulate feeding circuits via mTOR activation. Indeed, Rip-Tsc1cKO mice displayed increased mTOR signaling and enlarged neuron cell size in a number of hypothalamic populations, including Pomc neurons. Furthermore, Tsc1 deletion with Pomc/Cre (Pomc-Tsc1cKO mice) resulted in dysregulation of Pomc neurons and hyperphagic obesity. Treatment with the mTOR inhibitor, rapamycin, ameliorated the hyperphagia, obesity, and the altered Pomc neuronal morphology in developing or adult Pomc-Tsc1cKO mice, and cessation of treatment reinstated these phenotypes. Thus, ongoing mTOR activation in Pomc neurons blocks the catabolic function of these neurons to promote nutrient intake and increased adiposity.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19356717 PMCID: PMC2790375 DOI: 10.1016/j.cmet.2009.03.005
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287